The negative predictive value of FDG PET/CT staging in early oropharyngeal squamous cell carcinoma and implications to transoral robotic surgery patient selection.
Adult
Humans
Squamous Cell Carcinoma of Head and Neck
/ pathology
Oropharyngeal Neoplasms
/ diagnostic imaging
Robotic Surgical Procedures
Positron Emission Tomography Computed Tomography
Fluorodeoxyglucose F18
Predictive Value of Tests
Retrospective Studies
Carcinoma, Squamous Cell
/ diagnostic imaging
Patient Selection
Head and Neck Neoplasms
/ pathology
Neoplasm Staging
De-escalation strategies
FDG-PET
Head and neck neoplasms
Human papillomavirus 16
Squamous cell carcinoma
Transoral robotic surgery
Journal
Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
23
03
2022
revised:
12
09
2022
accepted:
10
10
2022
pubmed:
25
10
2022
medline:
29
11
2022
entrez:
24
10
2022
Statut:
ppublish
Résumé
Our objective was to determine the negative predictive value (NPV) of preoperative FDG PET/CTfor detecting locoregional nodal disease. The aim was to help inform the decision-making process when identifying patients with early-stage OPSCC that would be suitable for transoral robotic surgery (TORS) as a single-modality treatment. A retrospective cohort study was conducted of adults with primary stage cT1-2 OPSCC with up to one metastatic neck lymph node (cN0-1) planned for TORS. Patients with a preoperative PET/CT and who had undergone staging neck dissection (ND) were included. Clinical and pathological nodal staging was established based on PET/CT and ND, respectively. The primary outcome was the frequency of occult (not seen on PET/CT) nodal disease on ND. Eighty-eight patients were included (N = 88). The rate of occult nodal disease was 28.4 % (n = 25). The NPV of PET/CT in the clinically negative neck was 79 % and 66 % in cases with a single clinical node. Following staging ND, thetreatment plan changed in 27 % of cases overall, 7 % in cN0 and 36.7 % in cN1. Among these, 18 % met criteria for radiotherapy and 9 % for CRT. This represented a decrease in the number of ideal candidates for TORS as single-modality treatment from 88 to 64 (73 %). PET/CT is a useful tool in the workup of patients for primary TORS. However, about one third of patients with early-stage OPSCC might benefit from adjuvant therapy not predicted by preoperative PET/CT. A staging ND helps confirm candidates for single-modality treatment with TORS.
Identifiants
pubmed: 36274346
pii: S1368-8375(22)00502-4
doi: 10.1016/j.oraloncology.2022.106213
pii:
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106213Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.